|Bid||2.0100 x 0|
|Ask||2.0500 x 0|
|Day's Range||2.0100 - 2.4200|
|52 Week Range||1.5250 - 3.8800|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
WKN: A1C4WM) today announced that it has agreed to terms to acquire a 51% ownership interest in Gaia Pharm Lda ., a license applicant in Portugal , to establish a local facility to produce medical cannabis and derivative products. The company will be renamed "Aurora Portugal Lda".
WKN: A1C4WM) announced today that Michael Singer , previously Chairman of the Board, has been appointed Executive Chairman of the Board of Directors. The Company also announced that independent director Ronald Funk has been named Lead Independent Director and Margaret ("Sha n") Atkins has been appointed as a new independent director and Chair of the Audit Committee.
WKN: A1C4WM) today announced that the Company's construction of a 300,000 square foot expansion at the Edmonton International Airport is progressing well. The new facility, named Aurora Polaris, is intended to serve as Aurora's centre of excellence for the industrial-scale production of higher margin, value added products, such as edibles which Health Canada regulations propose to permit from October 2019 onwards.
Aurora Cannabis Announces Confirmed Time for its Conference Call to Discuss Second Quarter 2019 Results
In 2016, Aurora identified Radient's proprietary extraction technology (MAP™) as potentially disruptive for the cannabis industry due to its ability to achieve much higher throughputs than is possible with existing benchmark technologies, as well as its efficiency and ability to preserve the full spectrum of cannabinoids and terpenes found in the source material.
"These convertible notes offer Aurora the flexibility and optionality to settle the entire principal amount of the notes in the future for cash, shares, or combination thereof," said Aurora CEO Terry Booth . Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth.
The Company will issue US$300.0 million aggregate principal amount of notes, or US$345.0 million aggregate principal amount if the initial purchasers' over-allotment option is exercised in full. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth.
Aurora also intends to grant to the initial purchasers of the notes an option to purchase up to an additional US$37.5 million aggregate principal amount of notes. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth. The final terms of the notes will be determined by Aurora and the initial purchasers.
WKN: A1C4WM) today provided an expected revenue range for the second quarter of the Company's Fiscal 2019 ("Q2 2019"), the period ended December 31, 2018 . Based on preliminary (unaudited) results, the Company anticipates revenues for Q2 2019 of between $50 million and $55 million (net of excise taxes), compared to $11.7 million for the same quarter in the prior year, and compared to $29.7 million for the previous quarter ended September 30, 2018 ("Q1 2019"). The results reflect an anticipated revenue growth rate in excess of 327% compared to Q2 2018 and in excess of 68% compared to Q1 2019.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
/THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES ABSENT SUCH REGISTRATION OR AN APPLICABLE EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS. WKN: A1C4WM) ("Aurora") as well as 1,330 Debentures to other Offering participants for gross proceeds to date of $11,330,000 .
WKN: A1C4WM) announced today that, further to the Company's press release dated December 7, 2018 , the Company has entered into a Letter of Intent to acquire all of the issued and outstanding shares of Farmacias Magistrales S.A. ("Farmacias"), subject to customary due diligence provisions, the completion of definitive agreements, and regulatory and government approval. As previously announced, Farmacias recently became Mexico's first and only federally licensed importer to date of raw materials containing THC, gaining the necessary licenses, facilities, and permissions to import raw THC material, and manufacture, store, and distribute medical cannabis products containing over 1% THC.
Aurora Cannabis to Enter Mexico Market via Exclusive Supply Arrangement with Farmacias Magistrales